ADMA生物制品

最新新闻

• 评级变动
  Cantor Fitzgerald Downgrades ADMA Biologics(ADMA.US) to Hold Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/3/26
• 公司公告
  ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
  SEC · 2026/3/11
• 评级变动
  Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2025/5/9
• 评级变动
  Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2025/8/18
• 公司公告
  ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
  SEC · 2026/4/4
• 评级变动
  Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/4/21
• Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 公司公告
  ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
  SEC · 2026/2/24
• 评级变动
  Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $24
  \u5e02\u573a\u8d44\u8baf · 2026/4/14
• 公司公告
  4: ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
  SEC · 2026/7/29
• 评级变动
  Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Hold Rating, Cuts Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 公司公告
  ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Director Guiheen Lawrence P.
  SEC · 2026/3/18
• ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
  Benzinga · 2026/8/6
• 评级变动
  Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2025/5/9
• Raymond James Initiates ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/6/10
• 评级变动
  CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/5/5
• 评级变动
  Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2025/11/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。